Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04740164 · ClinicalTrials.gov registry record · NA

A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP

A NA study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
NA
Development phase
66
Enrollment target

NCT04740164: Completed NA study, sponsored by M.D. Anderson Cancer Center.

NCT04740164 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 66 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04740164, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
NA
Development phase
66 participants
Enrollment target

Study Summary

This clinical trial compares the effect of LMA Gastro, a dual channel supraglottic airway (SGA) device, to oxygenation with standard nasal cannula for endoscopic retrograde cholangiopancreatography (ERCP). An ERCP is a combination of imaging scans and endoscopy that helps doctors diagnose and treat conditions of the pancreas and bile ducts that requires general anesthesia or procedural sedation. Anesthesiologists often use SGAs or nasal cannulas to help patients breathe while they are asleep during procedures. An SGA consists of an airway tube that connects to a mask, which is inserted through the mouth and placed at the back of the throat to keep the airway open while patients are under anesthesia or sedation. The nasal cannula is a device that fits in a patient's nostrils and delivers oxygen through a small, flexible tube while they are under anesthesia or sedation. The goal of this trial is to compare the effects of the LMA Gastro to nasal cannula when used to deliver oxygen to patients while they are asleep during their ERCP procedure.

Primary Outcome

The desaturation (SpO2 \< 90%) between patients undergoing ERCP with LMA® Gastro™ vs standard nasal cannula

Interventions

  • PROCEDURE Endoscopic Retrograde Cholangiopancreatography

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2021-02-24
Est. Completion 2023-05-04
Phase NA
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT04740164 record still lists

NCT04740164 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which Endoscopic Retrograde Cholangiopancreatography is the first listed.

NCT04740164 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04740164 about?

NCT04740164 is a clinical study titled "A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP". This clinical trial compares the effect of LMA Gastro, a dual channel supraglottic airway (SGA) device, to oxygenation with standard nasal cannula for endoscopic retrograde cholangiopancreatography (ERCP). An ERCP is a combination of imaging scans and endoscopy that helps doctors diagnose and treat ...

What is the current status of trial NCT04740164?

This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2021-02-24. Estimated completion is 2023-05-04.

What interventions are being tested in trial NCT04740164?

The interventions under investigation include: Endoscopic Retrograde Cholangiopancreatography (PROCEDURE).

Who is sponsoring clinical trial NCT04740164?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04740164's enrollment target sits among peer trials

66 1139th of 2000 higher than 857 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02584244 · 66 participants · Phase 1

    Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

  • NCT03067051 · 66 participants · Phase 1

    Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

  • NCT03754725 · 66 participants · Phase 1

    Ferritin and Iron Burden in SAH sIRB

  • NCT03875378 · 66 participants · Phase 2

    Transdermal Estrogen in Women With Anorexia Nervosa

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04740164, the US trial registry maintained by the National Library of Medicine. NCT04740164 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.